Current Phase I Trials for Solid Tumors

Share
Print
Share
Print
  • A Phase I Study of Nivolumab and Ipilimumab Immunotherapy for Advanced HIV-Related Solid Tumors, including Hodgkin Lymphoma
  • A Phase I Study of Pyrotinib for HER2-Positive or Mutant Cancers 
  • A Phase I Study of Entrectinib in Children and Adolescents with Persistent or Recurrent Solid Tumors in the Body or Brain
  • A Phase I Study of Intraperitoneal Radioimmunotherapy with 131I-8H9 for Patients with Desmoplastic Small Round Cell Tumors and Other Solid Peritoneal Tumors
  • A Phase I Study of Oral RGX-104 Immunotherapy for Patients with Recurrent or Persistent Advanced Solid Tumors and Lymphoma
  • A Phase IB Study of ARQ 092 plus Other Anticancer Therapies in Patients with Recurrent or Persistent Solid Tumors
  • A Phase I Study of DS-3032B in Patients with Advanced Solid Tumors or Lymphomas
  • A Phase IIA Study of ALRN-6924 in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma
  • A Phase I Study of Debio1347 in Patients with Advanced Cancers Containing FGFR Alterations
  • A Phase I Study of LTT462 in Patients with Advanced Cancers that Have an Altered MAPK Signaling Pathway
  • A Phase I Study of LXH254 in Patients with Advanced Cancers that Have an Altered MAPK Signaling Pathway
  • A Phase I Study of MSC-1 in Patients with Advanced Cancers
  • A Phase I Study of Carfilzomib plus Cyclophosphamide and Etoposide for Children with Recurrent or Persistent Solid Tumors and Leukemias
  • A Phase I/II Study of CX-2009 to Treat Patients with Inoperable or Metastatic Solid Tumors
  • A Phase I Study of BLU-285 in Patients with Inoperable Gastrointestinal Stromal Tumors
  • A Phase I Study of MVT-1075 Radioimmunotherapy in Patients with Recurrent or Persistent Pancreatic Cancer
  • A Phase IIA Study of ALRN-6924 in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma
  • A Phase I Study of TNO155 to treat Advanced Solid Tumors
  • A Phase I Study of an Arginine Methyltransferase Inhibitor (PRMT5, GSK3326595) in Patients with Solid Tumors and Non-Hodgkin Lymphoma
  • A Phase I Study of DS-8201A in Patients with Advanced Solid Tumors
  • A Phase I Study of LOXO-292 in Patients with Advanced Solid Tumors
  • A Phase I Study of LY3321367 with or without LY3300054 Immunotherapy in Patients with Advanced Solid Tumors
  • A Phase I Study of Olaratumab Alone and with Chemotherapy in Children with Solid Tumors
  • A Phase IB Study of IPI-549 Alone or with Nivolumab Immunotherapy in Patients with Advanced Solid Tumors
  • A Phase I Study of Immunotherapy with BMS-986016 Alone and with Nivolumab in Patients with Advanced Solid Tumors
  • A Phase IIA Study of ALRN-6924 in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma